Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
13.29
+0.25 (1.92%)
At close: Jul 1, 2026, 4:00 PM EDT
13.55
+0.26 (1.96%)
After-hours: Jul 1, 2026, 6:46 PM EDT
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $760.99 million as of July 1, 2026. Its market cap has increased by 786.72% in one year.
Market Cap
760.99M
Enterprise Value
615.17M
1-Year Change
786.72%
Ranking
Category
Stock Price
$13.29
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $760.99M, an increase of 88.74%. That is a compound annual growth rate of 13.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 1, 2026 | 760.99M | 298.47% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | 403.20M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aura Biosciences | 783.13M |
| SL Science Holding | 774.18M |
| Candel Therapeutics | 754.68M |
| SpyGlass Pharma | 750.75M |
| Tenax Therapeutics | 743.39M |
| Aclaris Therapeutics | 738.82M |
| Immix Biopharma | 733.97M |
| Relmada Therapeutics | 725.84M |